European Journal of Heart Failure

JANUARY 17, 2025

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: a FIDELITY analysis. The incidence of hyperkalaemia leading to hospitalization or study drug discontinuation was low across treatment groups irrespective of diuretic use. Out of 12990 patients, 51.6%

Kidney Disease 40

Kidney Disease Diabetes Myocardial Infarction Heart Failure 40

Circulation

NOVEMBER 11, 2024

Background:Empagliflozin is a sodium glucose co-transporter 2 inhibitor that improves cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidney disease and heart failure. vs 5.4%), and hospitalization for heart failure (RR 0.66; 95% CI [0.58, 0.76]; P < 0.00001; 3.2%

Myocardial Infarction 40

Myocardial Infarction Blood Pressure Heart Failure Kidney Disease 40

DAIC

APRIL 6, 2024

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. To have a 25% to 30% reduction in heart failure hospitalizations is pretty clinically meaningful, but if you put it together with all-cause mortality, it was not a positive study for our primary endpoint.”

Heart Attack 98

Heart Attack Heart attacks Heart Failure Outpatient 98

Dr. Smith's ECG Blog

APRIL 8, 2016

He also had a history of chronic kidney disease, stage III. Angio had shown some acute disease in the saphenous vein graft to the posterior descending artery off of the RCA. Literature on Hypokalemia as a risk for ventricular fibrillation in acute myocardial infarction. Most recent echo showed EF of 60%.

STEMI 52

STEMI Myocardial Infarction Cardiac Arrest Arrhythmia 52

European Journal of Heart Failure

DECEMBER 12, 2023

Abstract Objectives This study aimed to assess the impact of anemia and iron deficiency (ID) on clinical outcome in patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI). ID has no relevant impact on clinical outcome in patients with CS.

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Outcomes Catheterization Laboratory 40

DAIC

APRIL 6, 2024

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24, 24, being held in Atlanta, GA.

Heart Attack 81

Heart Attack Heart attacks Heart Failure Outcomes 81

Journal of the American Heart Association

MARCH 21, 2025

Study end points include mortality, cardiovascular events (hospitalization for acute myocardial infarction or stroke) and limb events (hospitalization for critical limb ischemia or major amputation) and were identified using Veterans Affairs and nonVeterans Affairs encounters.ResultsThe mean age was 70.6 At 1 year, 9.4%

Peripheral Arterial Disease 45

Peripheral Arterial Disease Outcomes Myocardial Infarction Kidney Disease 45

DAIC

JANUARY 23, 2024

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Cardiometabolic Health Congress

JULY 25, 2023

Patients with heart failure for instance, have continuous changes in fluid status, which is unfortunately part of the pathophysiology of the disease which ultimately leads to increased risk for hospitalizations, and using BMI may often misclassify a patient as overweight or obese.

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Frontiers in Cardiovascular Medicine

DECEMBER 18, 2024

BackgroundInflammation significantly impacts chronic kidney disease (CKD) and acute myocardial infarction (AMI). After adjusting above two indicators, NLR was independently associated with in-hospital MACCE in CKD patients with AMI (OR=10.764, 95% CI: 1.88761.406, P=0.007).

Myocardial Infarction 52

Myocardial Infarction Kidney Disease Risk Factors Hospital 52

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. Disparities in care are also concerning, with diagnosed cardiometabolic diseases varying up to twofold among different racial and ethnic groups. In the U.S.,

CME 103

CME Obesity Heart Failure Biomarkers 103